| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
A randomized phase II trial of personalized peptide vaccine plus low dose estramustine phosphate (EMP) versus standard dose EMP in patients with castration resistant prostate cancer.
|
Cancer Immunol Immunother
|
2010
|
1.70
|
|
2
|
Immunologic evaluation of personalized peptide vaccination for patients with advanced malignant glioma.
|
Clin Cancer Res
|
2005
|
1.65
|
|
3
|
A phase II study of personalized peptide vaccination combined with gemcitabine for non-resectable pancreatic cancer patients.
|
Oncol Rep
|
2010
|
1.07
|
|
4
|
Assessment of immunological biomarkers in patients with advanced cancer treated by personalized peptide vaccination.
|
Cancer Biol Ther
|
2010
|
1.04
|
|
5
|
Immunological evaluation of personalized peptide vaccination in combination with UFT and UZEL for metastatic colorectal carcinoma patients.
|
Cancer Immunol Immunother
|
2009
|
1.02
|
|
6
|
Overcoming the hurdles of randomised clinical trials of therapeutic cancer vaccines.
|
Eur J Cancer
|
2010
|
0.96
|
|
7
|
A phase I study of personalized peptide vaccination for advanced urothelial carcinoma patients who failed treatment with methotrexate, vinblastine, adriamycin and cisplatin.
|
BJU Int
|
2010
|
0.96
|
|
8
|
Personalized peptide vaccination for advanced biliary tract cancer: IL-6, nutritional status and pre-existing antigen-specific immunity as possible biomarkers for patient prognosis.
|
Exp Ther Med
|
2011
|
0.93
|
|
9
|
Induction of cytokines by toxins that have an identical RNA N-glycosidase activity: Shiga toxin, ricin, and modeccin.
|
Biochim Biophys Acta
|
2004
|
0.92
|
|
10
|
Phase I clinical study of a personalized peptide vaccination for patients infected with hepatitis C virus (HCV) 1b who failed to respond to interferon-based therapy.
|
Vaccine
|
2007
|
0.91
|
|
11
|
PD-1 expression on peripheral blood T-cell subsets correlates with prognosis in non-small cell lung cancer.
|
Cancer Sci
|
2014
|
0.90
|
|
12
|
Dissection and identification of regions required to form pseudoparticles by the interaction between the nucleocapsid (N) and membrane (M) proteins of SARS coronavirus.
|
Virology
|
2008
|
0.89
|
|
13
|
Characteristics of severe adverse events after peptide vaccination for advanced cancer patients: Analysis of 500 cases.
|
Oncol Rep
|
2011
|
0.89
|
|
14
|
Protein-bound polysaccharide K induced apoptosis of the human Burkitt lymphoma cell line, Namalwa.
|
Biomed Pharmacother
|
2004
|
0.88
|
|
15
|
ABCE1, a member of ATP-binding cassette transporter gene, encodes peptides capable of inducing HLA-A2-restricted and tumor-reactive cytotoxic T lymphocytes in colon cancer patients.
|
Oncol Rep
|
2005
|
0.87
|
|
16
|
Phase I clinical study of a peptide vaccination for hepatitis C virus-infected patients with different human leukocyte antigen-class I-A alleles.
|
Cancer Sci
|
2009
|
0.87
|
|
17
|
Two proliferation-related proteins, TYMS and PGK1, could be new cytotoxic T lymphocyte-directed tumor-associated antigens of HLA-A2+ colon cancer.
|
Clin Cancer Res
|
2004
|
0.86
|
|
18
|
A phase II study of a personalized peptide vaccination for chemotherapy-resistant advanced pancreatic cancer patients.
|
Oncol Rep
|
2013
|
0.86
|
|
19
|
Increased levels of IgG antibodies against peptides of the prostate stem cell antigen in the plasma of pancreatic cancer patients.
|
Oncol Rep
|
2007
|
0.85
|
|
20
|
Juzentaihoto Failed to Augment Antigen-Specific Immunity but Prevented Deterioration of Patients' Conditions in Advanced Pancreatic Cancer under Personalized Peptide Vaccine.
|
Evid Based Complement Alternat Med
|
2013
|
0.85
|
|
21
|
Humoral immune responses to CTL epitope peptides from tumor-associated antigens are widely detectable in humans: a new biomarker for overall survival of patients with malignant diseases.
|
Dev Comp Immunol
|
2013
|
0.84
|
|
22
|
An HLA-A3-binding prostate acid phosphatase-derived peptide can induce CTLs restricted to HLA-A2 and -A24 alleles.
|
Cancer Immunol Immunother
|
2009
|
0.84
|
|
23
|
Capability of SART3(109-118) peptide to induce cytotoxic T lymphocytes from prostate cancer patients with HLA class I-A11, -A31 and -A33 alleles.
|
Int J Oncol
|
2009
|
0.84
|
|
24
|
Immunological evaluation of personalized peptide vaccination in refractory small cell lung cancer.
|
Cancer Sci
|
2012
|
0.83
|
|
25
|
Selection criteria for high risk and low risk groups of recurrence and metastasis in patients with primary colorectal cancer.
|
Oncol Rep
|
2003
|
0.83
|
|
26
|
Identification of B cell epitopes reactive to human papillomavirus type-16L1- derived peptides.
|
Virol J
|
2012
|
0.83
|
|
27
|
Long-term survival and tumor 5-FU sensitivity in patients with stage IV colorectal cancer and peritoneal dissemination.
|
Oncol Rep
|
2006
|
0.83
|
|
28
|
Phase I trial of a cancer vaccine consisting of 20 mixed peptides in patients with castration-resistant prostate cancer: dose-related immune boosting and suppression.
|
Cancer Immunol Immunother
|
2015
|
0.82
|
|
29
|
Criteria for predicting the recurrence and metastasis of stage I and II gastric cancer without lymph node metastasis.
|
Oncol Rep
|
2004
|
0.82
|
|
30
|
Evaluation of a new oil adjuvant for use in peptide-based cancer vaccination.
|
Cancer Sci
|
2010
|
0.82
|
|
31
|
Identification of two novel tumor-associated antigens recognized by HLA-B46-restricted cytotoxic T lymphocytes.
|
Int J Mol Med
|
2003
|
0.82
|
|
32
|
Identification of peptides applicable as vaccines for HLA-A26-positive cancer patients.
|
Cancer Sci
|
2009
|
0.82
|
|
33
|
A peptide derived from hepatitis C virus (HCV) core protein inducing cellular responses in patients with HCV with various HLA class IA alleles.
|
J Med Virol
|
2009
|
0.81
|
|
34
|
Haptoglobin proved a prognostic biomarker in peripheral blood of patients with personalized peptide vaccinations for advanced castration-resistant prostate cancer.
|
Biosci Biotechnol Biochem
|
2013
|
0.81
|
|
35
|
Sensitivity to CPT-11 and platinum derivatives of stage I/II node-negative breast, lung, and gastric cancer with occult neoplastic cells in lymph node sinuses.
|
Oncol Rep
|
2007
|
0.80
|
|
36
|
Development of a new diagnostic tool for pancreatic cancer: simultaneous measurement of antibodies against peptides recognized by cytotoxic T lymphocytes.
|
Kurume Med J
|
2006
|
0.79
|
|
37
|
Dexamethasone did not suppress immune boosting by personalized peptide vaccination for advanced prostate cancer patients.
|
Prostate
|
2008
|
0.78
|
|
38
|
Predicting recurrence and metastasis of stage III/Dukes' C colorectal cancer with lymph node metastasis.
|
Oncol Rep
|
2004
|
0.78
|
|
39
|
Identification of epidermal growth factor receptor-derived peptides recognised by both cellular and humoral immune responses in HLA-A24+ non-small cell lung cancer patients.
|
Eur J Cancer
|
2004
|
0.78
|
|
40
|
Recurrence and 5-FU sensitivity of stage II/III node-positive gastric cancer with occult neoplastic cells in lymph node sinuses.
|
Oncol Rep
|
2005
|
0.78
|
|
41
|
A new epitope peptide derived from hepatitis C virus 1b possessing the capacity to induce cytotoxic T-lymphocytes in HCV1b-infected patients with HLA-A11, -A31, and -A33.
|
Cancer Immunol Immunother
|
2007
|
0.78
|
|
42
|
Recurrence and 5-FU sensitivity of stage I/II node-negative breast, lung, or gastric cancer with occult neoplastic cells in lymph node sinuses.
|
Oncol Rep
|
2006
|
0.78
|
|
43
|
Correlation between occult neoplastic cells in the lymph node sinuses and recurrence in patients with curatively resected Dukes' B colorectal cancer.
|
Oncol Rep
|
2003
|
0.77
|
|
44
|
Accuracy of criteria for predicting recurrence and metastasis in stage II and III gastric cancer patients with lymph node metastasis.
|
Oncol Rep
|
2004
|
0.77
|
|
45
|
Immunological evaluation of personalized peptide vaccination monotherapy in patients with castration-resistant prostate cancer.
|
Cancer Sci
|
2009
|
0.77
|
|
46
|
Identification of squamous cell carcinoma antigen-derived peptides having the capacity of inducing cancer-reactive CTLs in HLA-A24+ cancer patients.
|
Int J Oncol
|
2006
|
0.76
|
|
47
|
Predicting recurrence and metastasis of primary esophageal cancer with or without lymph node metastasis.
|
Oncol Rep
|
2006
|
0.76
|
|
48
|
Correlation between occult neoplastic cells in the lymph node sinuses and recurrence in patients with Dukes' C colorectal cancer.
|
Oncol Rep
|
2003
|
0.76
|
|
49
|
A unique gene having homology with the kinesin family member 18A encodes a tumour-associated antigen recognised by cytotoxic T lymphocytes from HLA-A2+ colon cancer patients.
|
Eur J Cancer
|
2005
|
0.76
|
|
50
|
Sensitivity to CPT-11 and platinum derivatives of stage II/Dukes' B colorectal cancer with occult neoplastic cells in lymph node sinuses.
|
Oncol Rep
|
2007
|
0.76
|
|
51
|
New peptides of the polycomb group protein enhancer of zeste homolog 2 with the potential to induce cancer-reactive cytotoxic T lymphocytes in human leukocyte antigen-A2+ prostate cancer patients.
|
Oncol Rep
|
2007
|
0.76
|
|
52
|
Phase I clinical study of a personalized peptide vaccination available for six different human leukocyte antigen (HLA-A2, -A3, -A11, -A24, -A31 and -A33)-positive patients with advanced cancer.
|
Exp Ther Med
|
2010
|
0.75
|
|
53
|
Prospective study on the recurrence/metastasis of stage II/III colorectal cancer and gastric cancer associated with occult neoplastic cells in lymph node sinuses: three-year interim results.
|
Oncol Rep
|
2006
|
0.75
|
|
54
|
Predicting recurrence and metastasis of Dukes' A primary colorectal cancer with or without proper muscle invasion.
|
Oncol Rep
|
2004
|
0.75
|
|
55
|
Recurrence and 5-FU sensitivity of stage II/Dukes' B colorectal cancer with occult neoplastic cells in lymph node sinuses.
|
Oncol Rep
|
2005
|
0.75
|
|
56
|
Recurrence and 5-FU sensitivity of stage III/Dukes' C colorectal cancer with occult neoplastic cells in lymph node sinuses.
|
Oncol Rep
|
2005
|
0.75
|
|
57
|
Identification of hepatitis C virus 1b-derived peptides recognized by both cellular and humoral immune systems in HCV1b(+) HLA-A24(+) patients.
|
Hepatol Res
|
2005
|
0.75
|
|
58
|
Predicting the recurrence/metastasis of stage II and III breast cancer with lymph node metastasis.
|
Oncol Rep
|
2004
|
0.75
|
|
59
|
Sensitivity to CPT-11 and platinum derivatives of stage III/Dukes' C colorectal cancer with occult neoplastic cells in lymph node sinuses.
|
Oncol Rep
|
2007
|
0.75
|
|
60
|
Predicting the recurrence/metastasis of stage I and II breast cancer without lymph node metastasis.
|
Oncol Rep
|
2004
|
0.75
|
|
61
|
Detection of IgE antibody specific to a hepatitis C virus-derived peptide being recognized by cellular immunity in patients with HCV infection.
|
Viral Immunol
|
2008
|
0.75
|
|
62
|
Predicting recurrence and metastasis of stage II/Dukes' B colorectal cancer without lymph node metastasis.
|
Oncol Rep
|
2004
|
0.75
|
|
63
|
Identification of hepatitis C virus (HCV) 2a-derived epitope peptides having the capacity to induce cytotoxic T lymphocytes in human leukocyte antigen-A24+ and HCV2a-infected patients.
|
Cell Immunol
|
2006
|
0.75
|